

Adipose tissue : A regulator for obesity and its complications

Abstract

Adipose tissue is a key player in whole body metabolism and excess adipose tissue poses a major risk factor for the development of metabolic disorders such as type 2 diabetes. In response to nutritional overload, de novo adipocyte differentiation can serve as an adaptive mechanism by increasing the storage capacity of adipose tissue and maintaining normal adipocyte function. This in turn prevents systemic lipid overload, which is a major cause for insulin resistance. Obesity results from the imbalanced energy intake for expenditure with excessive fat accumulation in adipose tissue. Obesity is associated with numerous metabolic disorders, including hyperlipidemia, diabetes mellitus, hypertension, stroke, osteoarthritis, infertility and certain types of cancer. Obesity is associated with chronic subclinical inflammation in which the metabolism of adipose tissue plays an important role. The adipose tissue is an endocrine organ which has a fundamental role in metabolic, inflammatory, cardiovascular homeostatic regulation through lipogenesis, lipolysis, steroidogenesis, and secretion of several biologically active adipokines with diverse protein structures and functions. Adipose tissue is of two types; the fat storing white adipose tissue and the thermogenic brown adipose tissue. While the former is implicated in obesity, insulin resistance and diabetes, the latter is a physiological anti-obesogenic and antidiabetic through adaptive thermogenesis by uncouplers proteins. This review article will mainly focus on the pathophysiological changes of adipose tissue fat during obesity in relation to energy expenditure towards prevention or development of obesity and its complications.

Keywords *Obesity, Metabolic syndrome, Insulin resistance, diabetes, Adipose tissue, White adipose tissue, Brown adipose tissue, Adipokines, Adaptive thermogenesis, Uncoupler proteins, Bile acids.*

Obesity at glance

Obesity is gaining attention as one of the major leading public health problems. The terms overweight and obesity are both labels for ranges of weight that are greater than generally considered healthy for a given height. Obesity is considered a situation of positive energy balance due to energy intake that exceeds energy consumption (surplus) leading to the storage of triacylglycerols in adipose tissue, ready to be mobilized when expenditure exceeds intake [1]. International Diabetes Federation defined obesity is a metabolic syndrome describing a cluster of factors associated with an increased risk for diabetes and atherosclerotic cardiovascular health problems. The causes of insulin resistance related to obesity are diverse. However the current modern sedentary life style, with lack of physical activity and an controlled over-nutrition and genetic predisposing factors supports metabolic diseases [2]. The prevalence of overweight and obesity has also increased in children and adolescents in developing countries from 1980 to 2013 [3] International Obesity Taskforce reported that 1.1 billion people are overweight and 312 million are classified as obese [4]. Among the global obesity prevalence, the US has attracted broad public attention as the high prevalence of obesity [33.8%] [5] followed by European and less developed countries as a factor of over-nutrition [6]. According to WHO, obesity is generally more common among women than men [7]. Previous reports revealed higher rates of obesity in female than in males [8]. However, studies on college students revealed higher rates of obesity in males than in females [9].

Obesity is considered a disorder of multifactorial aetiology since it is the sum of genetic, behavioral, life style and environmental factors, such as fetal programming, control of appetite, energy expenditure and availability, and nutritional content of food [49]. Obesity is commonly defined as body mass index ($\text{BMI} = \text{weight (in kg)} / \text{height (mm)}^2$) of 30 kg/m^2 or higher. This distinguishes it from being overweight as defined by a BMI of between $25\text{-}29.9 \text{ kg/m}^2$ (World Health Organization, 2000). The values above this are categorized as clinically obese. Within the defined 'obese' category there is further sub-division, as demonstrated in Table 1[50].

Adipose tissue and obesity

There are many different adipose tissue depots within the body. One special subclass is brown adipose tissue, which is especially developed in infants and small rodents, where it can be induced by cold exposure[56]. Brown adipocytes have many small lipid droplets, in contrast to white adipocytes, which have one large lipid core. The main function of brown adipocytes is the production of heat through expression of uncoupling-protein 1 (UCP1). It has long been believed that only children and rodents have brown adipose tissue, which is located in distinct pads adjacent to the shoulder blades. However, it has recently been shown that brown adipocytes exist in adult humans and are interspersed into the common white fat pads and might also be inducible by cold[57]. Inducing brown adipocytes by specific agents could therefore be an interesting novel therapeutic intervention to increase energy expenditure and treat obesity.

On the other hand, white adipose tissue represents the majority of body fat. Based on the localization adipose tissue depots can be classified as subcutaneous adipose tissue underneath the dermis or visceral adipose tissue within the cavities of the body. Most visceral adipose tissue lies within the abdominal cavity with the gonadal, the mesenteric and the retroperitoneal fat

compartments being the most prominent [58]. This distinction is not only of anatomical interest but also has functional implications. It has been shown that visceral and subcutaneous adipose tissue show distinct gene expression patterns[59]. Furthermore, visceral adipose tissue poses a greater risk for metabolic complications than subcutaneous adipose tissue[60]. The reasons for this are currently not clear. Potential explanations include that factors

secreted from the visceral adipose tissue drain directly into the portal vein or that adipocyte function itself is altered in different depots, which will be discussed further below. Due to hormonal differences, overweight women tend to have more subcutaneous adipose tissue, whereas overweight men show increased central adiposity and are thus more prone to metabolic complications[61]. Moreover, treatment with glitazones leads, amongst other things, to redistribution of fat to the subcutaneous compartment, thereby ameliorating the metabolic profile without causing weight loss[62].

In human body adipose tissue acts as a endocrine organ and plays an important role in the human metabolism [10]. It has essential metabolic functions in the body. Although excess amount of adipose tissue predisposes several metabolic complications. About 21% of adipose tissue accounts for an average man of 70 kg [11]. The excess of energy has stored in the form of triglycerides in the adipocytes in adipose tissue. Besides its obvious storage function, adipose tissue has mechanical functions such as insulation and protection against mechanical forces

Adipose tissue plays a potential role in obesity related chronic mild inflammation by secretion of several biologically active adipocytokines (Figure 1) including adiponectin, cytokines (tumor necrosis factor- α [TNF- α], leptin, interleukin-6 [IL-6], C-C motif chemokine ligand-2 [CCL2], and chemoattractant proteins [CCL receptor-2 [CCR2]) and some proteins have potential role in the regulation of angiogenesis or vascular homeostasis, blood pressure (plasminogen activator

inhibitor-1 [PAI-1] and angiotensinogen). Adipose tissue essential substances also regulates the carbohydrate, lipid metabolism [adiponectin and resistin], thermogenesis (uncoupling proteins [UCPs], coactivator-1 α [PGC-1] and PPAR- γ) and adipogenesis (peroxisome proliferator-activated receptor- γ [PPAR- γ]) [12].

Obesity is associated with a state of chronic, low-grade inflammation characterized by abnormal cytokine production and the activation of inflammatory signaling pathways in WAT [13]. Increased inflammatory cytokines play a critical role in obesity-related inflammation and metabolic pathologies. For example, TNF- α is an important cytokine that induces the production of IL-6 [14] is one of the major determinant of the acute phase response in the chronic inflammation and also has effects on lipid metabolism, insulin action and glucose transport [15].

Previous studies stated, reduction of adipose mass leads to the decrease the expression levels of TNF- α and IL-6 in obese individuals and animal models [15]. Additionally, TNF- α can also modulates leptin secretions whereas, reduction in body fat positively associated with decreased leptin circulating levels as well as its gene expression [16].

However, in cases of lipodystrophy the majority of normal adipose tissue depots are ectopically stored in extra-adipose tissue, leading to risk for a number of diverse conditions such as hypertension atherosclerosis, cancer and insulin resistance [17]. To understand the pathological and molecular changes in the adipose tissue in context to obesity and related complications has become complicated. However, adipose tissue malfunction in obesity causes increase lipolysis with concomitant release of excess non-esterified fatty acids results in the inhibition of glucose uptake in muscle as well as suppression of hepatic glucose output leading to insulin resistance as a secondary complications [17]. Elevated Free fatty acids (FFAs) also effect the fatty acid based signaling cascade [18], leads to the decreased vasodilatation and hypertension [19]. Furthermore,

intracellular fatty acids lead to activation of inflammatory pathways [20]. Moreover, serum elevated FFAs prove increase risk for myocardial infarction , cardiomyopathy[21] and enhance atherosclerosis [22]. Whereas, β -cells in the liver impaired glucose-stimulated insulin secretion for long term exposure to the elevated FFAs[23,24].

In obesity the adipocytokines profile of adipose tissue also undergoes a diverse changes apart from lipolysis. Hukshorn, C.J., et al., [25] reported that elevated levels of leptin in chronic inflammation state of obesity concomitantly impaired leptin signaling hence, unattractive target for the treatment of obesity. However, the levels of adiponectin are diminished in obesity as a exceptional adipokine [26,27]. In obese individuals the inflammatory cytokines are highly upregulated. For example, massive infiltration of macrophages due to secretions of high levels of monocyte chemoattractant protein 1 [MCP-1] from adipocytes [28]. The other proinflammatory cytokines either released from adipocytes or macrophages directly are IL-1 β , IL-6, TNF α , and C-reactive protein [CRP]. It is stated that visceral fat has more severe metabolic effects than subcutaneous fat because most of the cytokines are secreted to a greater extent from visceral adipose tissue [29]. Cytokines released from adipose tissue induce a systemic low-grade inflammation promoting insulin resistance [30]. Moreover, in obesity, TNF α inhibits triglyceride synthesis through downregulation of PPAR γ and its target gene LPL as well as glucose transporter GLUT4 and also inhibits insulin-mediated attenuation of lipolysis, down regulates the lipid droplet protein perilipin and up- regulates the cAMP pool, all of which further enhances the release of FFAs[31].

Adipose tissue and Energy Metabolism

Adipogenesis defined as a development of mature adipocyte from its multipotent mesenchymal stem cell. PPAR γ is a adipose tissue secreted molecule acts as a master regulator of

adipogenesis [32,33]. The isoform of PPAR γ such as PPAR- γ 2 is expressed in adipose tissue and responsible for the differentiation and proliferation of adipocytes leads to an increase in adipose mass and its gender dependent. [34-36]. In contrast, Brown adipose tissue [BAT] plays an potential role adaptative thermogenesis, White adipose tissue [WAT] act mainly as fat storage. BAT contains high number of mitochondria and small, multilocular lipid droplets aided in the adaptive thermogeneisis [37].

Several studies have focused on UCP families [UCP1, UCP2, and UCP3] role in the adaptive thermogenesis as a physiological defense against diabetes and obesity [38]. Argyropoulos G and Harper ME, [39] reported that significant UCP-1 expression in BAT for whole body energy expenditure and its dysfunction leads to the development of obesity. UCP1 is a unique mitochondrial membranous protein devoted to adaptive thermogenesis, a specialized function performed by brown adipocytes. Among the family of mitochondrial metabolite carriers UCP1 is the only member able to translocate protons through the inner membrane of brown adipocyte mitochondria (Figure 2). UCP1 provokes energy dissipation in the form of heat by uncouples respiration from ATP synthesis. UCP1 also stimulating high levels of fatty acid oxidation [40]. UCP2 is high degree of sequence similarity with UCP1 [55–60%] have been identified in both rodent and human tissues [41]. UCP3, is mainly expressed in human skeletal muscle and BAT [42].

The imbalance between energy intake and expenditure represent the major predisposing factor to contributing to obesity and its complications. Now a days the most of the drugs using in the treatment of obesity mainly targeting to the energy intake through gastrointestinal mechanisms without altering any central mechanisms such as nutrient digestion and absorption inhibitors. Previous studies showed that administration of BAs to mice increases energy expenditure in

brown adipose tissue, hence, Bile acids (BA's) came to light that, BAs have long been known to be essential in dietary lipid absorption and cholesterol catabolism. BAs acts as signaling molecules to activate mitogen-activated protein kinase pathways[43], are ligands for the G-protein-coupled receptor (GPCR) TGR5 [44,45]. Bile acids (BAs) promotes energy expenditure in BAT by activation of TGR5 leads to prevention of obesity and insulin resistance[46]. TGR5 plays an important role in energy expenditure to regulate body metabolism. Cyclic-AMP-dependent thyroid hormone activating enzyme type 2 iodothyronine deiodinase [D2] expression induced by BAs in human skeletal muscle and thermogenical tissues of mouse brown fat. In this tissue, binding of bile acids to the plasma membrane G protein-coupled bile acid receptor 1 [Gpbar1, also known as TGR5 triggers an increase in cyclic AMP formation and, subsequently, D2 expression. D2 subsequently converts thyroxine [T4] to tri-iodothyronine [T3]. T3 is predicted to induce uncoupling protein [UCP] expression in BAT. UCP is known to dissipate the proton gradient in the electron transport chain. Therefore, the activation of BAs/TGR5/cyclic AMP/D2/T3/UCP pathway cascade causes a decrease in the synthesis of ATP and thus regulates energy homeostasis [46].

Obesity and complications

Obesity is a major health concern, which leads to a reduction in life expectancy of nearly 8 years, and to several co-morbidities, including the metabolic syndrome consisting of insulin resistance, type 2 diabetes, cardiovascular disease, fatty liver disease, cancer, hypertension, stroke, dementia, and obstructive sleep apnoea [49,51,52]. A positive correlation between pain and obesity has also been reported in relation to several pathological conditions [53], and a negative relationship between obesity and quality of life has been identified using health-related quality of life scores, which include measures of pain, fatigue and physical functioning [54]. A number of

studies have shown that obese individuals also have increased susceptibility to systemic infections, are more likely to develop infectious complications after surgery, and are more susceptible to nosocomial diseases [55]. In addition, obesity has been found to have a serious negative impact on the individual's psychology and social life as a consequence of abnormal body image, prejudice, discrimination and limitations affecting daily life activities due to increased body weight (Obesity: preventing and managing the global epidemic. WHO consultation, 2000). Clearly the spread of obesity and its association with several complications, e.g. physical impairment, pain and other co-morbid disorders, including diabetes and cardiovascular diseases, strengthens the necessity to further understanding of the mechanisms underlying this pathological state and to achieve better quality of life for obese patients.

Conclusion

Adipose tissue as a endocrine organ acts as a primary storage of excess energy (WAT) as well as potential in adaptive thermogenesis (BAT). Adipose tissue secretes various adipocyte-specific factors known as adipokines such as leptin and adiponectin which show beneficial effects on insulin action and lipid metabolism. The derived cytokines (tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6)) from adipose tissue in obese individuals make understand the molecular link between inflammation, obesity and insulin resistance. The secretion of adipokines are directly proportional to the adipose tissue mass, promoting the idea that reducing total adipose mass may be a strategy for the treatment of obesity and its complications. Additionally, understanding the signaling pathways in target tissues such as the skeletal muscle , brain, and liver by which adipokines control metabolism , the signaling activation cascade of TGR5 by BAs and its role in energy expenditure in BAT, the molecular mechanisms responsible for macrophage polarization and targeting the mechanisms involved in macrophage recruitment

from the circulation may also helpful in the development of novel therapies for the obesity and its related complications.

References

1. Joosen, A. M., & Westerterp, K. R.. Energy expenditure during overfeeding. *Nutr Metab* 2006;3,25.
2. O'Rahilly, S: Human genetics illuminates the paths to metabolic disease. *Nature* 2009, 462:307-314.
3. Marie Ng et al.,: A systematic analysis for the Global Burden of Disease Study 2013. *The Lancet* 2014 , 384 (9945): 766-781
4. Haslam, D.W. & James, W.P: Obesity. *Lancet* 2005, 366:1197-1209.
5. Flegal, K.M., Carroll, M.D., Ogden, C.L. & Curtin, L.R: Prevalence and trends in obesity among US adults, 1999-2008. *JAMA* 2010,303:235-241.
6. Hossain, P., Kavar, B. & El Nahas, M : Obesity and diabetes in the developing world--a growing challenge. *N Engl J Med* 2007, 356:213-215.
7. World Health Organization: Obesity: preventing and managing the global epidemic. Report of a WHO consultation. *World Health Organ Tech Rep Ser* 2010, 894:1-253.
8. Berghofer, A., et al : Obesity prevalence from a European perspective: a systematic review. *BMC Public Health* 2008, 8: 200
9. Yahia N, Achkar A, Abdallah A, Rizk S: Eating habits and obesity among Lebanese university students. *Nutr J* 2008, 7:32.
10. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. *Archives of Medical Science: AMS* 2013;9(2):191-200.
11. Shen, W., et al: Adipose tissue quantification by imaging methods: A proposed classification. *Obesity Research* 2003, 11: 5-16.

12. Ebtesam A AL-Suhaimi and Adeeb Shehzad: Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Archives of Medical Science: AMS 2013, 9(2):191-200.
13. Jung UJ, Choi M-S. Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences 2014;15(4):6184-6223.
14. Hajri T, Tao H, Wattacheril J, Marks-Shulman P, Abumrad NN: Regulation of adiponectin production by insulin: interactions with tumor necrosis factor- α and interleukin-6. American Journal of Physiology - Endocrinology and Metabolism 2011, 300(2):E350-E360.
15. McArdle MA, Finucane OM, Connaughton RM, McMorrow AM, Roche HM: Mechanisms of Obesity-Induced Inflammation and Insulin Resistance: Insights into the Emerging Role of Nutritional Strategies. Frontiers in Endocrinology 2013, 4:52.
16. Sophie Carter, Alexandre Caron, Denis Richard, and Frédéric Picard : Role of leptin resistance in the development of obesity in older patients. Clin Interv Aging 2013, 8: 829–844.
17. Jianping Ye: Mechanisms of insulin resistance in obesity. Frontiers of medicine 2013, 7(1):14-24.
18. Roberts CK, Hevener AL, Barnard RJ: Metabolic Syndrome and Insulin Resistance: Underlying Causes and Modification by Exercise Training. Comprehensive Physiology 2013, 3(1):1-58.
19. Yong Wu, Hillary Zhou, Ke Wu, Sangkyu Lee, Ruijin Li, Xuan Liu: PTEN Phosphorylation and Nuclear Export Mediate Free Fatty Acid-Induced Oxidative Stress. Antioxidants & Redox Signaling 2014, 20(9):1382-1395.
20. Hellmann J, Zhang MJ, Tang Y, Rane M, Bhatnagar A, Spite M: Increased saturated fatty acids in obesity alter resolution of inflammation in part by stimulating prostaglandin production. Journal of immunology 2013, 191(3):1383-1392.
21. Pilz S, März W, Wellnitz B, et al : Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008, 93:3927–3935
22. Bamba, V. & Rader, D.J: Obesity and atherogenic dyslipidemia. Gastroenterology 2007, 132: 2181- 2190.
23. Jun Ho Kim, Hyung Taek Cho, Young Jun Kim: The role of estrogen in adipose tissue metabolism: insights into glucose homeostasis regulation . Endocrine Journal. 2014, 61 (11): 1055-1067.

24. Carpentier, A., et al: Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. *Am J Physiol* 1999, 276: E1055-1066.
25. Hukshorn, C.J., et al: The effect of pegylated recombinant human leptin [PEG-OB] on weight loss and inflammatory status in obese subjects. *Int J Obes Relat Metab Disord* 2002, 26:504-509.
26. Michael Rosenbaum and Rudolph L Leibel: 20 YEARS OF LEPTIN: What we know and what the future holds. *J Endocrinol* 2014, 223 : T83–T96.
27. Yatagai, T., et al: Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. *Metabolism* 2003, 52:1274-1278.
28. Panee J: Monocyte Chemoattractant Protein 1 (MCP-1) in Obesity and Diabetes. *Cytokine* 2012, 60(1):1-12.
29. Maury, E., et al: Adipokines oversecreted by omental adipose tissue in human obesity. *American journal of physiology* 2007, 293:E656-665.
30. Makki K, Froguel P, Wolowczuk I: Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells, Cytokines, and Chemokines. *ISRN inflammation* 2013, 2013:139239
31. Guilherme, A., Virbasius, J.V., Puri, V. & Czech, M.P: Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. *Nat Rev Mol Cell Biol* 2008, 9:367-377 .
32. Mori S, Kiuchi S, Ouchi A, Hase T, Murase T: Characteristic Expression of Extracellular Matrix in Subcutaneous Adipose Tissue Development and Adipogenesis; Comparison with Visceral Adipose Tissue. *International Journal of Biological Sciences* 2014, 10(8):825-833.
33. Rosen ED, Spiegelman BM: Molecular regulation of adipogenesis. *Annu Rev Cell Dev Biol* 2000, 16:145–171.
34. Garin-Shkolnik, T., Rudich, A., Hotamisligil, G. S., & Rubinstein, M: FABP4 Attenuates PPAR γ and Adipogenesis and Is Inversely Correlated With PPAR γ in Adipose Tissues. *Diabetes*, 2014, 63(3), 900-911.
35. Ogawa R, Mizuno H, Watanabe A, Migita M, Hyakusoku H, Shimada T: Adipogenic differentiation by adipose-derived stem cells harvested from GFP transgenic mice-including relationship of sex differences. *Biochem Biophys Res Commun.* 2004, 319:511–517.

36. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. *Cell* 1994, 79:1147–1156.
37. Kajimura S, Saito M: A New Era in Brown Adipose Tissue Biology: Molecular Control of Brown Fat Development and Energy Homeostasis. *Annual review of physiology* 2014, 76:225-249.
38. Cypess, Aaron M., and C. Ronald Kahn: Brown Fat as a Therapy for Obesity and Diabetes. *Current opinion in endocrinology, diabetes, and obesity* 2010, 17(2): 143–149.
39. Argyropoulos G, Harper ME: Uncoupling proteins and thermoregulation. *J Appl Physiol* 2002, 92:2187–2198.
40. Daniel Ricquier: Uncoupling protein1 of brown adipocytes, the only uncoupler: a historical perspective. *CellularEndocrinology* 2011,2.
41. Fleury C, Neverova M, Collins S, et al: Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. *Nat Genet* 1997, 15:269–72.
42. Vidal-Puig A, Solanes G, Grujic D, et al.: UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. *Biochem Biophys Res Commun* 1997, 235:79–82.
43. Gupta, S., Stravitz, R. T., Dent, P. & Hylemon, P. B: Down-regulation of cholesterol 7 α -hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. *J. Biol. Chem.* 2001, 276: 15816–15822 .
44. Kawamata, Y. et al: A G protein-coupled receptor responsive to bile acids. *J. Biol. Chem.* 2003, 278: 9435–9440 .
45. Maruyama, T. et al: Identification of membrane-type receptor for bile acids (M-BAR). *Biochem. Biophys. Res. Commun.* 2002, 298, 714–719.
46. Watanabe, M., et al: Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature* 2006, 439:484–489.
47. E. Maury, S.M. Brichard: Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. *Molecular and Cellular Endocrinology* 2010, 314: 1–16.
48. Bruce M. Spiegelman and Jeffrey S. Flier: Obesity and the Regulation of Energy Balance. *Cell*, Vol. 2001, 104:531–543.

49. Bluher, M. Adipose tissue dysfunction in obesity. *Exp Clin Endocrinol Diabetes*, 2009; 117(6),241-250.
50. Weisell, R. C. Body mass index as an indicator of obesity. *Asia Pac J Clin Nutr* 11 2002(8): S681-4.
51. Trayhurn, P., & Wood, I. S. . Signalling role of adipose tissue: adipokines and inflammation in obesity. *Biochem Soc Trans*, 2005;33(Pt 5), 1078-1081.
52. Galic, S., Oakhill, J. S., & Steinberg, G. R. Adipose tissue as an endocrine organ. *Mol Cell Endocrinol*, 2010;316(2), 129-139.
53. Grotle, M., Hagen, K. B., Natvig, B., Dahl, F. A., & Kvien, T. K.. Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up. *BMC Musculoskelet Disord*, 2008;9, 132.
54. Anandacoomarasamy, A., Smith, G., Leibman, S., Caters on, I., Giuffre, B., Fransen, M., Sambrook, P., & March, L. Cartilage defects are associated with physical disability in obese adults. *Rheumatology*, 2009;48(10), 1290-1293.
55. Janniger, C. K., Schwartz, R. A., Szepietowski, J. c., & Reich, A. Intertrigo and common secondary skin infections. *Am Fam Physician*, 2005;72(5), 833-838.
56. Cannon, B. & Nedergaard, J. Brown adipose tissue: function and physiological significance. *Physiol Rev* .2004;84, 277-359 .
57. Cypess, A.M., et al. Identification and importance of brown adipose tissue in adult humans. *N Engl J Med*. 2009;360, 1509-1517 .
58. Shen, W., et al. Adipose tissue quantification by imaging methods: A proposed classification. *Obesity Research*. 2003;11, 5-16 .
59. Vohl, M.C., et al. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. *Obesity Research*. 2004;12, 1217-1222.
60. Kissebah, A.H. & Krakower, G.R. Regional adiposity and morbidity. *Physiol Rev* .1994;74, 761-811.
61. Krotkiewski, M., Bjorntorp, P., Sjostrom, L. & Smith, U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. *J Clin Invest*. 1983;72, 1150-1162.
62. Smith, S.R., et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. *Metabolism* .2005;54, 24-32 .

Figure 1: Regulation of Adipokines in obesity and its complications.

Adiponectin (ApN), PAI-1, plasminogen activator inhibitor type 1; AGT, angiotensinogen; TNF- α , tumor necrosis factor- α ; RBP-4, retinol-binding protein-4; MCP-1, monocyte chemoattractant protein-1; IL-6, interleukin-6 [47].





Figure 2. Mitochondrial ATP Metabolism and adaptive thermogenesis through Proton Transport chain.

Ubiquinone (Q), cytochrome c (C), complexes I, II III, and IV of the electron transport chain, uncoupling protein (UCP), Nicotinamide adenine dinucleotide (NAD), Flavin adenine dinucleotide (FAD) [48].



398 Table 1: Table of the BMI scale, highlighting the classified limits

WHO classification for Europids	BMI (kg/m2)
Underweight	<18.5
Healthy/Lean	18.5-24.9
Overweight	25-29.9
Obese I	30-34.9
Obese II	35-39.9
Morbid Obesity	>40

399

400